LIGHTBEAM-U01-Substudy 01B: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination with Investigational Agents in Pediatric and Young Adult Participants with Hematologic Malignancies or Solid Tumors.

Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults

Part 1: Area Under the Curve (AUC), Part 1: Maximum Concentration (Cmax), Part 1: Concentration in the Blood Immediately Before the Next Dose (Ctrough), Part 1: Number of Participants Who Experience Dose-limiting Toxicities (DLTs), Parts 1 and 2: Number of Participants Who Report at Least 1 Adverse Event (AE), Parts 1 and 2 : Number of Participants Who Discontinue Study Drug Due to an AE, Parts 1 and 2: Objective Response Rate (ORR) per Lugano Response Criteria by Blinded Independent Central Review (BICR), Parts 1 and 2: ORR per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Investigator

Parts 1 and 2: ORR per Lugano Response Criteria by Investigator, Parts 1 and 2: Disease Control Rate (DCR) per Lugano Response Criteria by BICR, Parts 1 and 2: DCR per RECIST 1.1 by Investigator, Parts 1 and 2: Duration of response (DOR) per Lugano Response Criteria by BICR, Parts 1 and 2: DOR per RECIST 1.1 by Investigator, Parts 1 and 2: Progression Free Survival (PFS) per Lugano Response Criteria by BICR, Parts 1 and 2: PFS per RECIST 1.1 by Investigator, Parts 1 and 2: Overall Survival (OS), Part 2: Area Under the Curve (AUC), Part 2: Maximum Concentration (Cmax), Part 2: Concentration in the Blood Immediately Before the Next Dose (Ctrough), Parts 1 and 2: Antidrug Antibody (ADA) Levels, Parts and 2: Biomarkers for Classical Hodgkin Lymphoma (cHL)

No related papers found yet.

Denmark